According to ISUOG, what is the recommended timing of delivery for severe fetal growth restriction with reversed end‑diastolic flow in the umbilical artery and reversed a‑wave in the ductus venosus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Delivery Timing for Severe FGR with Reversed Umbilical Artery End-Diastolic Flow and Reversed Ductus Venosus A-Wave

The question asks about ISUOG guidelines, but the provided evidence is from SMFM (Society for Maternal-Fetal Medicine), not ISUOG. Based on SMFM guidelines, delivery should occur at 30-32 weeks of gestation for FGR with reversed end-diastolic flow in the umbilical artery 1.

Key Management Algorithm

When Reversed End-Diastolic Flow is Detected:

Immediate actions:

  • Hospitalize the patient 1
  • Administer antenatal corticosteroids if <33 6/7 weeks 1
  • Initiate cardiotocography monitoring at least 1-2 times daily 1
  • Plan delivery at 30-32 weeks gestation (GRADE 1B recommendation) 1

Critical Caveat About Ductus Venosus Assessment:

SMFM explicitly recommends AGAINST using ductus venosus Doppler for routine clinical management of FGR (GRADE 2B) 1. This creates a clinical dilemma since your question specifically mentions reversed DV a-wave, but the guideline states this finding should not guide routine management decisions.

However, the guideline does state that delivery timing should consider "the entire clinical picture and results of additional evaluation of fetal well-being" 1. This suggests that while DV Doppler shouldn't be used routinely, when abnormal findings are present, they may inform the urgency of delivery within the recommended 30-32 week window.

Evidence from Research Studies:

Research data provides important context that supports earlier delivery when DV abnormalities are present:

  • Abnormal DV Doppler waveforms (absent or reversed a-wave) are strongly associated with perinatal death (R² = 0.57, P < 0.001) and adverse outcomes (R² = 0.86, P < 0.001) in preterm FGR with ARED flow 2

  • All cases of fetal death in one large cohort showed either reversed end-diastolic flow in the umbilical artery OR abnormal ductus venosus Doppler at the examination preceding death 3

  • The risk of fetal death increases progressively: from 0.6% with intermittent absent end-diastolic flow to 11.5% with reversed end-diastolic flow 3

Practical Clinical Approach:

Given the combination of reversed umbilical artery end-diastolic flow PLUS reversed DV a-wave, this represents the most severe end of the FGR spectrum. While SMFM guidelines recommend delivery at 30-32 weeks for reversed UA flow alone, the presence of abnormal DV findings suggests:

  1. Aim for delivery closer to 30 weeks rather than 32 weeks within the recommended window
  2. Consider delivery even earlier if <30 weeks if additional signs of fetal decompensation appear (abnormal cardiotocography, hydrops, etc.)
  3. Intensify surveillance to at least twice-daily cardiotocography 1
  4. Strongly consider cesarean delivery based on the clinical scenario (GRADE 2C) 1

Additional Management Points:

  • Administer magnesium sulfate for neuroprotection if delivery will occur <32 weeks (GRADE 1A) 1
  • Ensure antenatal corticosteroids are given if delivery anticipated before 33 6/7 weeks (GRADE 1A) 1
  • Monitor Doppler 2-3 times per week once absent end-diastolic velocity is detected 1

Important Distinction:

The SMFM guideline's recommendation against routine DV use doesn't mean ignore it when abnormal—it means don't routinely obtain it for management decisions. When you have this information showing reversed a-wave alongside reversed UA flow, you're dealing with a fetus showing severe cardiovascular compromise, which warrants delivery at the earlier end of the 30-32 week recommendation or potentially earlier depending on the complete clinical picture.

Related Questions

What is the most appropriate management for an intrauterine growth‑restricted fetus at 25 weeks + 6 days gestation with persistent absent end‑diastolic flow in the umbilical arteries and an absent a‑wave in the ductus venosus?
What is the most appropriate management for a 24‑week + 2‑day pregnant patient with fetal growth restriction and persistent absent end‑diastolic flow in the umbilical arteries?
What evidence supports and opposes inpatient versus outpatient management for a fetus with fetal growth restriction and absent end‑diastolic flow in the umbilical arteries?
What evidence guides the optimal timing of delivery for a growth‑restricted fetus with an absent or reversed a‑wave in the ductus venosus?
What is the typical time interval between absent diastolic flow and reversed end-diastolic flow in the umbilical artery (UA) of a growth-restricted fetus?
What does the Society of Maternal‑Fetal Medicine (SMFM) recommend for managing fetal growth restriction when reversal of the a‑wave in the ductus venosus is observed?
What are the signs and symptoms of gallstones and pancreatitis?
Why should a patient with gestational diabetes take metformin during pregnancy?
What is the clinical significance of an erythrocyte sedimentation rate of 68 mm/hr?
In a liver transplant recipient receiving tacrolimus (or cyclosporine), mycophenolate mofetil, and low‑dose prednisone, what dental precautions—including need for antibiotic prophylaxis and hemostatic management—are recommended for routine dental cleaning and for tooth extraction?
What should I do for uncontrollable jerking movements occurring during a workout?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.